Calcitonin products and therapies for treating inflammatory or degenerative diseases

Abstract

Calcitonin products and therapies for treating inflammatory or degenerative diseases are disclosed herein. The pharmaceutical compositions disclosed herein include a first therapeutic agent that is calcitonin, in free or salt form; a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid; and a pharmaceutically acceptable excipient, carrier or diluent. The methods disclosed herein for treating inflammatory or degenerative diseases in a subject include administering a therapeutically effective amount of calcitonin, in free or salt form, to the subject; and co-administering, as part of a combination therapy, a therapeutically effective amount of a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid to the subject.

What is claimed is: 
     
         1 . A method for treating a degenerative or an inflammatory disease in a subject comprising:
 administering a therapeutically effective amount of calcitonin, in free or salt form, to the subject; and   co-administering, as part of a combination therapy, a therapeutically effective amount of a second therapeutic agent selected from the group consisting of a matrix metalloproteinase inhibitor, an interleukin antagonist, an aggrecanase inhibitor, a tetracyline antibiotic, and a non-steroidal anti-inflammatory drug (NSAID) to the subject.   
     
     
         2 . The method of  claim 1  wherein the calcitonin is selected from the group consisting of human calcitonin, salmon calcitonin, eel calcitonin and elcatonin. 
     
     
         3 . The method of  claim 1  wherein the calcitonin is salmon calcitonin. 
     
     
         4 . The method of  claim 1  wherein the matrix metalloproteinase inhibitor is selected from one of galardin or BB-94. 
     
     
         5 . The method of  claim 1  wherein the calcitonin and the second therapeutic agent are each administered to the subject orally. 
     
     
         6 . The method of  claim 1 , wherein the NSAID is selected from the group consisting of aspirin, ibuprofen, naproxen, valdecoxib, celecoxib, etoricoxib and rofecoxib. 
     
     
         7 . The method of  claim 6  wherein the calcitonin is selected from the group consisting of human calcitonin, salmon calcitonin, eel calcitonin and elcatonin. 
     
     
         8 . The method of  claim 6  wherein the calcitonin is salmon calcitonin. 
     
     
         9 . The method of  claim 1  wherein the tetracycline antibiotic is doxycycline. 
     
     
         10 . The method of  claim 9  wherein the calcitonin and the tetracycline antibiotic are each administered to the subject orally. 
     
     
         11 . A pharmaceutical composition for the treatment of a degenerative or an inflammatory disease comprising:
 a first therapeutic agent that is calcitonin, in free or salt form;   a second therapeutic agent selected from the group consisting of a matrix metalloproteases inhibitor, an interleukin antagonist, an aggrecanase inhibitor, a tetracyline antibiotic, and a non-steroidal anti-inflammatory drug (NSAID); and   a pharmaceutically acceptable excipient, carrier or diluent.   
     
     
         12 . The pharmaceutical composition of  claim 11  wherein the second therapeutic agent is a matrix metalloproteases inhibitor. 
     
     
         13 . The pharmaceutical composition of  claim 11  wherein the second therapeutic agent is an interleukin antagonist. 
     
     
         14 . The pharmaceutical composition of  claim 11  wherein the second therapeutic agent is an aggrecanase inhibitor. 
     
     
         15 . The pharmaceutical composition of  claim 11  wherein the second therapeutic agent is a tetracyline antibiotic. 
     
     
         16 . The pharmaceutical composition of  claim 11  wherein the second therapeutic agent is a NSAID. 
     
     
         17 . The pharmaceutical composition of  claim 11  wherein the second therapeutic agent is administered at a dosage no higher than 90% of the normal dosage for the second therapeutic agent when administered alone. 
     
     
         18 . The pharmaceutical composition of  claim 11 , wherein the composition is an aqueous nasal spray. 
     
     
         19 . The pharmaceutical composition of  claim 11 , wherein the composition is a solid dosage form. 
     
     
         20 . The pharmaceutical composition of  claim 11  wherein the calcitonin is salmon calcitonin. 
     
     
         21 . The method of  claim 1 , wherein the calcitonin and the second therapeutic agent are administered as a single pharmaceutical composition. 
     
     
         22 . The method of  claim 1 , wherein the calcitonin and the second therapeutic agent are administered separately. 
     
     
         23 . The method of  claim 1 , wherein the second therapeutic agent is administered at a dosage no higher than 90% of the normal dosage for the second therapeutic agent when administered alone.